Navigating Wealth Drug Development as a Serial Biotech Entrepreneur ft. Eric Green, M.D., Ph.D. | Navigating Wealth
9 snips
Jan 14, 2026 In this engaging conversation, Eric Green, M.D., Ph.D., a physician-scientist and co-founder of Trace Neuroscience, dives into the world of biotech and genetics-driven therapies. He shares groundbreaking insights on ALS and the pivotal UNC-13A protein, revealing how understanding human genomics can lead to innovative treatments. Eric discusses the challenges of designing clinical trials for severe diseases and the importance of contract manufacturers in biotech innovation. Tune in for a fascinating look at how biotechnology is evolving in the wake of COVID-19!
AI Snips
Chapters
Transcript
Episode notes
Academic Research Fuels Biotech Translation
- Eric Green transitioned from academic medicine to biotech to apply genomic discoveries at scale for patients.
- Biotech startups can translate basic research into medicines outside the academic timeline.
Complementary Roles: Academia And Industry
- Basic research discovers foundational technologies like CRISPR that industry alone rarely invents.
- Biotech depends on academia for curiosity-driven breakthroughs and on companies to productize them.
Prioritize Early Clinical Proof
- Raise venture capital willing to fund pre-revenue development since early biotech rarely has revenue.
- Focus on demonstrating early clinical proof because small clinical readouts often create most value.